The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Newer antidepressants and the cytochrome P450 system
Abstract
OBJECTIVE: This review evaluates the in vitro and in vivo evidence for inhibition of cytochrome P450 enzymes by the newer antidepressants and provides clinical recommendations for avoiding and managing drug interactions. METHOD: The international literature on the cytochrome P450 system and related drug interactions from 1966 to 1995 was reviewed. In vitro studies, pharmacokinetic trials in human subjects, and case reports were assessed. RESULTS: The newer antidepressants each inhibit a different cluster of cytochrome P450 enzymes, which are of relevance to the potential for drug interactions. Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophylline, clozapine, and others. Fluoxetine, norfluoxetine, sertraline, and paroxetine are potent in vitro inhibitors of cytochrome P450 2D6 and are capable of causing marked elevations in plasma desipramine and nortriptyline concentrations. Fluoxetine, sertraline, and fluvoxamine are believed to inhibit cytochrome P450 2C because of observed interactions with phenytoin, diazepam, and other drugs metabolized by these enzymes. Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines. Plasma concentrations of these drugs have increased when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline. CONCLUSIONS: The majority of the newer antidepressants are associated with a risk for clinically significant drug interactions. A rapidly growing body of literature provides evidence for a distinct profile of cytochrome P450 inhibition and drug interaction risks by individual antidepressants. These findings underscore the need for definitive in vivo interaction studies of plasma from phenotyped patients treated with clinically effective antidepressant doses of medication, for direct comparative clinical studies, and for studies assessing the utility of phenotyping in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00025a009 · Cited by 601
Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R., & Smith, R. L. (1980) · Journal of Medical Genetics · doi:10.1136/jmg.17.2.102 · Cited by 536
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
Human liver carbamazepine metabolism
Kerr, B. M., Thummel, K. E., Wurden, C. J., Klein, S. M., Kroetz, D. L., Gonzalez, F. J., & Levy, R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90071-x · Cited by 433
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
van Harten, J. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00003 · Cited by 311
Genetic polymorphism of S-mephenytoin hydroxylation
Wilkinson, G. R., Peter Guengerich, F., & Branch, R. A. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90047-8 · Cited by 292
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Br�sen, K., & Gram, L. F. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637732 · Cited by 282
Jerling, M., Lindström, L., Bondesson, U., & Bertilsson, L. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199408000-00006 · Cited by 281
Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
Guengerich, F. P. (1990) · Chemical Research in Toxicology · doi:10.1021/tx00016a015 · Cited by 279
Pharmacokinetics of antidepressants: why and how they are relevant to treatment.
Cummings, J. L. (1993) · PubMed · Cited by 262
148th Annual Meeting of the American Psychiatric Association
(1996) · European Addiction Research · doi:10.1159/000319611 · Cited by 259
Inhibition by fluoxetine of cytochrome P450 2D6 activity
Otton, S. V., Wu, D., Joffe, R. T., Cheung, S. W., & Sellers, E. M. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.43 · Cited by 257
Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Säwe, J., & Villén, T. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.40 · Cited by 249
The relationship between paroxetine and the sparteine oxidation polymorphism
Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G., et al. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.23 · Cited by 205
Speculations on the Substrate Structure-Activity Relationship (SSAR) of cytochrome P450 enzymes
Smith, D. A., & Jones, B. C. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90333-e · Cited by 203
Br�sen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H., & Gram, L. F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316471 · Cited by 193
Pharmacokinetics of Desipramine Coadministered With Sertraline or Fluoxetine
PRESKORN, S. H., ALDERMAN, J., CHUNG, M., HARRISON, W., MESSIG, M., & HARRIS, S. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00002 · Cited by 190
Recent Developments in Hepatic Drug Oxidation: Implications for Clinical Pharmacokinetics
Brosen, K. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018030-00004 · Cited by 183
P450 Enzymes: Inhibition Mechanisms, Genetic Regulation and Effects of Liver Disease
Murray, M. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223020-00005 · Cited by 182
Species Differences in Metabolism and Pharmacokinetics: Are We Close to an Understanding?
Smith, D. A. (1991) · Drug Metabolism Reviews · doi:10.3109/03602539109029764 · Cited by 181
Lemoine, A., Gautier, J. C., Azoulay, D., Kiffel, L., Belloc, C., Guengerich, F. P., Maurel, P., Beaune, P., & Leroux, J. P. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13662-6 · Cited by 178
von Moltke, L. L., Greenblatt, D. J., Court, M. H., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199504000-00008 · Cited by 176
A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients
Dunbar, G. C., Cohn, J. B., Fabre, L. F., Feighner, J. P., Fieve, R. R., Mendels, J., & Shrivastava, R. K. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.159.3.394 · Cited by 175
CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans
Jacqz-Aigrain, É., Funck‐Brentano, C., & Cresteil, T. (1993) · Pharmacogenetics · doi:10.1097/00008571-199308000-00004 · Cited by 168
Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
Bergstrom, R. F., Peyton, A. L., & Lemberger, L. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.18 · Cited by 168
Elevated Levels of Clozapine in Serum After Addition of Fluvoxamine
HIEMKE, C., WEIGMANN, H., H??RTTER, S., DAHMEN, N., WETZEL, H., & M??LLER, H. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199408000-00011 · Cited by 163
Inhibitors of imipramine metabolism by human liver microsomes.
Skjelbo, E., & Brosen, K. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04133.x · Cited by 163
Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
Pan-Zhou, X.-R., Sérée, E., Zhou, X. J., Placidi, M., Maurel, P., Barra, Y., & Rahmani, R. (1993) · PubMed · Cited by 163
Moltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38622-2 · Cited by 156
Human cytochrome P-450 enzymes
Guengerich, F. P. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90136-d · Cited by 153
Increased carbamazepine plasma concentrations after fluoxetine coadministration
Grimsley, S. R., Jann, M. W., Carter, J. G., D’mello, A. P., & D’Souza, M. J. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.98 · Cited by 151
Fluoxetine impairs clearance of alprazolam but not of clonazepam
Greenblatt, D. J., Preskorn, S., Cotreau, M. M., Horst, W. D., & Harmatz, J. S. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.175 · Cited by 137
Fleishaker, J. C., & Hulst, L. K. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00195913 · Cited by 134
The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.
Bloomer, J. C., Woods, F. R., Haddock, R. E., Lennard, M., & Tucker, G. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04082.x · Cited by 133
Knodell, R. G., Hall, S. D., Wilkinson, G. R., & Guengerich, F. P. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00222-8 · Cited by 132
Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects
Spina, E., Pollicino, A., Avenoso, A., Campo, G. M., Perucca, E., & Caputi, A. P. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199306000-00011 · Cited by 132
Characterization of dextromethorphan N-demethylation by human liver microsomes
Gorski, J. C., Jones, D. R., Wrighton, S. A., & Hall, S. D. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90237-2 · Cited by 120
Elevation of plasma concentrations of haloperidol after the addition of fluoxetine
GOFF, D. C., Midha, K. K., Brotman, A. W., WAITES, M., & Baldessarini, R. J. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.790 · Cited by 117
Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine
Tate, J. L. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.399b · Cited by 114
The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam
Lemberger, L., Rowe, H., Bosomworth, J., Tenbarge, J. B., & Bergstrom, R. (1988) · Clinical pharmacology and therapy · doi:10.1038/clpt.1988.52 · Cited by 112
Pharmacokinetics of the newer antidepressants: Clinical relevance
DeVane, C. L. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90359-x · Cited by 110
Tyndale, R. F., KALOW, W., & Inaba, T. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05588.x · Cited by 106
(1995) · PubMed · Cited by 105
Lasher, T., Fleishaker, J. C., Steenwyk, R. C., & Antal, E. J. (1991) · Psychopharmacology · doi:10.1007/bf02246031 · Cited by 96
Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers
Perucca, E., Gatti, G., Cipolla, G., et al. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.167 · Cited by 94
Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Daniel, D. G., Randolph, C., Jaskiw, G. E., Handel, S., Williams, T., Abi‐Dargham, A., Shoaf, S. E., Egan, M. F., Elkashef, A., & LIBOFF, S. (1994) · PubMed · Cited by 94
Genetic polymorphisms of drug metabolism*
Meyer, U., Zanger, U. M., Skoda, R. C., Grant, D., & Blum, M. (1990) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1990.tb00041.x · Cited by 92
Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy
Sperber, A. D. (1991) · Drug Safety · doi:10.2165/00002018-199106060-00006 · Cited by 89
Fluvoxamine-tricyclic antidepressant interaction
Bertschy, G., Vandel, S., Vandel, B., Allers, G., & Volmat, R. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315151 · Cited by 85
Interaction between carbamazepine and fluvoxamine
Fritze, J., Unsorg, B., & Lanczik, M. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03200.x · Cited by 83
No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin
Andersen, B. B., Mikkelsen, M., Vesterager, A., Dam, M., Kristensen, H. B., Pedersen, B., Lund, J., & Mengel, H. B. (1991) · Epilepsy Research · doi:10.1016/0920-1211(91)90013-6 · Cited by 78
Bannister, S. J., Houser, V. P., Hulse, J. D., et al. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07186.x · Cited by 70
Reimherr, F. W., Byerley, W., Ward, M. F., Lebegue, B., & Wender, P. H. (1988) · PubMed · Cited by 70
Recent Developments in Drug Metabolism of Relevance to Psychiatrists
Pollock, B. G. (1994) · Harvard Review of Psychiatry · doi:10.3109/10673229409017138 · Cited by 68
Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.
Pollock, B. G., Mulsant, B. H., Sweet, R. A., Rosen, J., Altieri, L. P., & Perel, J. M. (1995) · PubMed · Cited by 60
Tricyclic Antidepressant Plasma Levels after Fluoxetine Addition
Vandel, S., Bertschy, G., Bonin, B., et al. (2008) · Neuropsychobiology · doi:10.1159/000118838 · Cited by 57
Inhibition of Trazodone Metabolism by Thioridazine in Humans
Yasui, N., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Ishida, M., Mihara, K., Kondo, T., Sugawara, K., & Fukushima, Y. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199508000-00003 · Cited by 55
Carbamazepine Coadministration with Fluoxetine or Fluvoxamine
Avenoso, A., Pollicino, A., Caputi, A. P., Fazio, A., & Pisani, F. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199306000-00012 · Cited by 53
Genetic Polymorphisms of Drug Metabolism
Meyer, U., Zanger, U. M., Grant, D. M., & BLUM, M. (1990) · Advances in Drug Research · doi:10.1016/b978-0-12-013319-2.50007-3 · Cited by 53
Selective serotonin reuptake inhibitor dose titration in the naturalistic setting.
Gregor, K. J., Overhage, J. M., Coons, S. J., & McDonald, R. C. (1994) · PubMed · Cited by 50
Preskorn, S., & Magnus, R. D. (1994) · PubMed · Cited by 49
Serotonin Syndrome Produced by Paroxetine and Low-Dose Trazodone
Reeves, R. R., & Bullen, J. A. (1995) · Psychosomatics · doi:10.1016/s0033-3182(95)71694-2 · Cited by 38
Fluoxetine Inhibition of Phenytoin Metabolism
Shader, R. I., Greenblatt, D. J., & Moltke, L. L. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00001 · Cited by 38
Bluhm, R. E., Wilkinson, G. R., Shelton, R. C., & Branch, R. A. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.13 · Cited by 38
S-mephenytoin 4-hydroxylation in older Americans
Pollock, B. G., Perel, J. M., Kirshner, M. A., et al. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00279979 · Cited by 34
Potential Terfenadine-Fluoxetine Interaction
Swims, M. P. (1993) · Annals of Pharmacotherapy · doi:10.1177/106002809302701119 · Cited by 32
Spina, E., Pollicino, A., Avenoso, A., et al. (1993) · PubMed · Cited by 28
Augmentation regimens for depression.
Nemeroff, C. B. (1991) · PubMed · Cited by 28
Evaluation of the Effect of Fluoxetine on the Formation of Carbamazepine Epoxide
Gidal, B. E., Anderson, G. D., Seaton, T., Miyoshi, H. R., & Wilenksy, A. J. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199310000-00008 · Cited by 26
Fluoxetine and parkinsonism in patients taking carbamazepine
Hb, G., van der Woude, J., & Touw, D. J. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1604b · Cited by 26
Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?
Bonnet, P., Vandel, S., Nezelof, S., Sechter, D., & Bízouard, P. (1992) · PubMed · Cited by 23
Therapeutic interchange of fluoxetine and sertraline: Experience in the clinical setting
Stock, A. J., & Kofoed, L. (1994) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/51.18.2279 · Cited by 21
Cited by
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects
Louik, C., Lin, A. E., Werler, M. M., Hernández-Díaz, S., & Mitchell, A. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067407 · Cited by 500
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479
“Furthermore, antidepressant-antipsychotic combinations are especially prone to adverse drug-drug interactions mainly because of the effects of antidepressants on the cytochrome P450 system.(49) For example, both fluoxetine and fluvoxamine significantly increase the serum level of concomitantly used clozapine.”
Background
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1996-03-01
- Volume
- 153
- Issue
- 3
- Pages
- 311-320
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2416351818
- Cited by
- 482
- References
- 78
- FWCI
- 66.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.